functions and regulation of the pten gene in colorectal cancer

Clicks: 273
ID: 205398
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #135 of 207 articles by views in international journal of heat and technology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 207 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PTEN is a tumor suppressor gene located at chromosome 10q23.31, encoding for a 403-amino acid protein that possesses both lipid and protein phosphatase activities. The main function of PTEN is to block the PI3K pathway by dephosphorylating phosphatidylinositol (PI) 3,4,5 triphosphate to phosphatidylinositol (PI)-4,5-bisphosphate thus counteracting PI3K function. PTEN inactivation is a frequent event in many cancer types and can occur through various genetic alterations including point mutations, large chromosomal deletions and epigenetic mechanisms.
In colorectal cancer (CRC) PTEN is altered through mixed genetic/epigenetic mechanisms, which lead to the biallelic inactivation of the protein in 20-30% of cases.
The role of PTEN as a prognostic and predictive factor in CRC has been addressed by relatively few works. This review is focused on the report and on the discussion of the studies investigating these aspects. Overall, at the moment, there are conflicting results and, therefore it has not been clarified whether PTEN might play a prognostic role in CRC. The same is valid also for the predictive role, leading to the fact that PTEN evaluation cannot be used in routinely diagnosis for the early identification of patients who might be addressed to the treatment with EGFR-targeted therapies, at odds with other genetic alterations belonging to EGFR-downstream pathways. The reason of discordant results may be attributable to several issues: 1) the size of the analysed cohort, 2) patients inclusion criteria, 3) the methods of assessing PTEN alteration. In particular, there are no standardized methods to evaluate this marker, especially for immunohistochemistry, a technique suffering of intra and inter-observer variability due to the semi-quantitative character of such an analysis
In conclusion, much work has to be done before the establishment of PTEN as prognostic or predictive marker in CRC.
Reference Key
emolinari2014frontiersfunctions Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Francesca eMolinari;Milo eFrattini
Journal international journal of heat and technology
Year 2014
DOI
10.3389/fonc.2013.00326
URL
http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00326/full
Keywords
prognosis mutation colorectal cancer pten immunohistochemistry Oncology including cancer and carcinogens tumors

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.